Disturbing News About AstraZeneca's Covishield Vaccine: TTS and Symptoms

TTS

AstraZeneca has acknowledged that its COVID-19 vaccine can lead to a rare blood clotting condition known as Thrombosis with Thrombocytopenia Syndrome (TTS).

Covishield and TTS

Covishield, developed by AstraZeneca and Oxford University, can, in rare instances, lead to Thrombosis with Thrombocytopenia Syndrome (TTS). Covishield is manufactured by the Serum Institute of India.

What is TTS?

Thrombosis with Thrombocytopenia Syndrome (TTS) is characterised by blood clots in blood vessels along with a low platelet count. It can occur in rare instances following certain types of vaccines, including adenovirus vector vaccines like Covishield.

Symptoms of TTS

Symptoms of TTS may include severe headaches, abdominal pain, leg swelling, or shortness of breath, typically appearing within two weeks after vaccination. Immediate recognition and treatment are crucial to lower the risk of serious complications.

Importance of Vaccination

While TTS is a rare side effect, the benefits of COVID vaccination outweigh the risks. Vaccines remain critical in controlling the spread of the virus, preventing severe illness, and saving lives. Awareness of TTS symptoms is essential for prompt medical attention if needed.

Concern

TTS is a rare but significant concern associated with AstraZenecas COVID-19 vaccine. Collaboration between healthcare professionals, regulatory agencies, and the public is crucial to ensuring the safety and effectiveness of vaccination efforts.